Shots:
- Eli Lilly has reported P-III (BRUIN CLL-313) trial data assessing Jaypirca (pirtobrutinib; 200mg, PO, QD) vs chemoimmunotherapy (bendamustine + rituximab) in 282 pts with 1L chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) without 17p deletions
- Trial met its 1EP of improved PFS per IRC, while OS was immature but showed a favorable trend & will be tested for significance at the primary OS analysis expected in 2026
- Additionally, results from the P-III (BRUIN CLL-313) & P-III (BRUIN CLL-314) studies will support planned label expansions into earlier lines of therapy, with global regulatory submissions expected to begin later this year
Ref: Eli Lilly | Image: Eli Lilly| Press Release
Related News:- The US FDA Grants Breakthrough Therapy Designation to Eli Lilly’s Olomorasib for KRAS G12C-Mutant NSCLC
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
